( October 6, 2025, 10:26 GMT | Official Statement) -- MLex Summary: Curium Pharma may not acquire the Barcelona Institute of Applied Radiopharmacy, or IRAB, the Spanish antitrust enforcer said on Monday. The agency cited "insurmountable competition risks" in the markets for the supply of PSMA radiopharmaceuticals, used in prostate cancer detection, and in the provision of contract manufacturing services to third parties in north-eastern Spain. The decision isn't final, the watchdog said, with the deal to be referred to the Minister of Economy to decide whether to send it to the Council of Ministers to assess it under "general-interest" aspects.Statement follows. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.